Kia Cuts EV Sales Target for 2030 Amid Slowing Demand and U.S. Policy Shifts 
Chinese Cars in Europe: Consumer Trust Is Shifting Fast 
U.S. Automakers Push Back Against EU Rules Blocking American Trucks from European Market 
Abbott Laboratories Ordered to Pay $53 Million in Premature Infant Formula Lawsuit 
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis 
BHP's Incoming CEO Visits China Amid Pricing Dispute with CMRG 
Tokyo Electric Power Attracts Major Investors Amid Billion-Dollar Restructuring Push 
Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts 
Alibaba Shares Slide as Jefferies Slashes Price Target Over AI Spending and Business Losses 
Anthropic's Mythos AI Model Sparks Emergency Cybersecurity Meeting With Top U.S. Bank CEOs 
Bill Ackman Eyes New Fund to Bet Against Market Complacency 
NIO ES9 SUV Launch Sends HK Shares Down 7% Despite Bold Pricing Strategy 
Pilots Fear Retaliation for Refusing Middle East Flights Amid Ongoing Conflict 
OpenAI Addresses Security Vulnerability in macOS App Certification Process 
San Francisco Suspect Arrested After Molotov Cocktail Attack on OpenAI CEO Sam Altman's Home 
Pony.ai, Uber, and Verne Launch Europe's First Commercial Robotaxi Service in Zagreb 
Foreign Investors Pour $18.65 Billion into Japanese Stocks Amid Market Stabilization 
SAN DIEGO, Feb. 15, 2017 -- Retrophin, Inc. (Nasdaq:RTRX) today announced it will report fourth quarter and full year 2016 financial results on Wednesday, March 1, 2017 after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss the financial results and provide a general business update at 5:00 p.m. ET.
Conference Call Information
| Date: | Wednesday, March 1, 2017 | |
| Time: | 5:00 p.m. ET | |
| Dial-in numbers: | +1 (855) 219-9219 (U.S.) or +1 (315) 625-6891 (International) | |
| Confirmation code: | 70808962 | |
| Live webcast: | www.retrophin.com in the "Events & Presentations" section of the "Investors" page | |
A replay of the call will be available from 8:00 p.m. ET, March 1, 2017 to 8:00 p.m. ET, March 8, 2017. The replay number is +1 (855) 859-2056 (U.S.) or +1 (404) 537-3406 (International), confirmation code 70808962.
About Retrophin
Retrophin is a fully integrated biopharmaceutical company dedicated to delivering life-changing therapies to people living with rare diseases who have few, if any, treatment options. The Company’s approach centers on its pipeline featuring late-stage assets targeting rare diseases with significant unmet medical needs, including sparsentan for focal segmental glomerulosclerosis (FSGS), a disorder characterized by progressive scarring of the kidney often leading to end-stage renal disease, and RE-024 for pantothenate kinase-associated neurodegeneration (PKAN), a life-threatening neurological disorder that typically begins in early childhood. Research exploring the potential of early-stage assets in several rare diseases is also underway. Retrophin’s R&D efforts are supported by revenues from the Company’s commercial products Thiola®, Cholbam® and Chenodal®.
Contact: Chris Cline, CFA Senior Director, Investor Relations 646-564-3680 [email protected]
